Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009 Nov;58(11):2427-8.
doi: 10.2337/db09-9030.

Insulin glargine controversy: a tribute to the editorial team at Diabetologia

Peter C Butler
Editorial

Insulin glargine controversy: a tribute to the editorial team at Diabetologia

Peter C Butler. Diabetes. 2009 Nov.
No abstract available

PubMed Disclaimer

References

    1. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732–1744 - PMC - PubMed
    1. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G: Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 2009;52:1745–1754 - PubMed
    1. Colhoun HM.SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755–1765 - PMC - PubMed
    1. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766–1777 - PubMed
    1. Smith U, Gale EA: Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699–1708 - PubMed

Publication types